Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer

Gelijkaardige items

• Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers
  door: Vojnic, Morana, et al.
  Gepubliceerd in: (2019)
• Activation of KRAS mediates resistance to targeted therapy in MET exon 14 mutant non-small cell lung cancer
  door: Suzawa, Ken, et al.
  Gepubliceerd in: (2018)
• Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
  door: Yu, Helena A., et al.
  Gepubliceerd in: (2015)
• Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
  door: Offin, Michael, et al.
  Gepubliceerd in: (2018)
• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
  door: Offin, Michael, et al.
  Gepubliceerd in: (2018)